BridgeMD
TADalafil in early-stage Parkinson’s Disease (TAD-PD)
EU CTIS ID: 2025-521819-39-00
What this study is testing
To assess whether daily tadalafil improves motor symptoms in Parkinson-drug naïve patients with early-stage Parkinson’s disease over a two-week follow-up period
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis of early-stage Parkinson’s disease, with no limitations in daily functioning that would necessitate symptomatic treatment
- No prior medication for Parkinson’s disease.
- Normal blood pressure (between >90/60 mm Hg and <120/80 mm Hg).
- Age older than 18 years.
- Informed consent and comply with the study protocol.
- Understand the Dutch language.
You likely can't join if
- Currently taking PDE-inhibitors for erectile dysfunction.
- (unstable) Cardiovascular and cerebrovascular disease.
- Unilateral blindness, hereditary retinal disorders, or increased risk of blindness.
- Unilateral deafness or history of severe hearing loss dependent upon hearing aid(s).
- Multisystem atrophy (MSA).
- Abnormal electrocardiogram (ECG).
See the full eligibility criteria
- Diagnosis of early-stage Parkinson’s disease, with no limitations in daily functioning that would necessitate symptomatic treatment
- No prior medication for Parkinson’s disease.
- Normal blood pressure (between >90/60 mm Hg and <120/80 mm Hg).
- Age older than 18 years.
- Informed consent and comply with the study protocol.
- Understand the Dutch language.
- Currently taking PDE-inhibitors for erectile dysfunction.
- (unstable) Cardiovascular and cerebrovascular disease.
- Unilateral blindness, hereditary retinal disorders, or increased risk of blindness.
- Unilateral deafness or history of severe hearing loss dependent upon hearing aid(s).
- Multisystem atrophy (MSA).
- Abnormal electrocardiogram (ECG).
- Orthostatic hypotension: a decrease in systolic blood pressure ≥ 20 mmHg, or a decrease in diastolic blood pressure ≥ 10 mmHg.
- Immunocompromised.
- Mild cognitive impairment (MCI) or dementia.
- Pregnancy and breastfeeding.
- Legally incompetent adults.
- Clinically significant penile deformity.
- Concurrent nitrate, nitric oxide donors, guanylate cyclase, nicorandil, theophylline alpha-blocker, cytochrome P-450 3A4 (CYP3A4) inhibitor/inducer, or prostacyclin analog use.
- Suspicion of or a known history of renal (eGFR level < 80 ml/min) or hepatic insufficiency.
- Significant alcohol or drug abuse.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.